After surgery to remove liver cancer, many patients worry about one question: Will it come back? A new study suggests a drug called pembrolizumab may help lower that risk.
The study looked at adults with hepatocellular carcinoma, the most common type of liver cancer. These patients had surgery or a procedure to destroy the tumor, and imaging showed no cancer left. Then they received either pembrolizumab or a placebo.
This matters because liver cancer is rising worldwide, and recurrence after surgery is common. Current options after surgery are limited, and many patients and families live with constant worry. A safe, effective way to reduce that risk could change lives.
For years, doctors relied on surgery and close monitoring after liver cancer treatment. The old thinking was to wait and watch for signs of return. But here’s the twist: new drugs that help the immune system may be able to find and clear tiny leftover cancer cells.
Think of the immune system like a security team patrolling a building. Pembrolizumab is like removing a blindfold from the guards. It helps the immune system spot and respond to cancer cells that might otherwise hide. In liver cancer, this approach may stop those cells from growing into a new tumor.
The study enrolled 959 participants and ran from 2019 to 2025. It compared pembrolizumab to a placebo after complete tumor removal by surgery or local ablation. Doctors checked for cancer return using standardized imaging reviews to keep the results fair and consistent.
The main goals were two: how long patients lived without cancer returning (recurrence-free survival) and how long they lived overall (overall survival). The study was designed to see if pembrolizumab could beat placebo on both measures.
Early results suggest pembrolizumab may help people live longer without cancer coming back. The exact numbers will be shared in detail when the full results are published. The overall survival data are still maturing, which is common in cancer studies that follow patients over time.
But there’s a catch. These findings are early, and longer follow-up is needed to confirm how much benefit patients truly gain and for how long. Not every patient will respond the same way, and some may have side effects.
Experts in liver cancer see this as a meaningful step. Adjuvant therapy—treatment after surgery—has been an area of unmet need in hepatocellular carcinoma. If pembrolizumab proves consistently beneficial, it could become part of routine care for selected patients.
What this means for you or a loved one: If you’ve had surgery or ablation for liver cancer and imaging shows no remaining tumor, ask your oncologist about adjuvant immunotherapy options. Pembrolizumab is already used for some advanced liver cancers, but its role after surgery is still being defined. Do not start or stop any treatment without medical guidance.
The study has limitations. It focused on patients with a complete radiological response after surgery or ablation, so results may not apply to everyone with liver cancer. Longer follow-up and real-world data are needed to understand long-term benefits and risks.
Next, researchers will continue monitoring overall survival and analyze subgroups to see who benefits most. Regulatory reviews will follow, and if the data hold up, pembrolizumab could become a new option after liver cancer surgery.